

"Leading scientific breakthroughs, driving transformative success."

About Me: Dedicated and proactive professional in medical research, with a proven track record in leading challenging clinical trials and medical biotechnology research projects, showcasing exceptional attention to detail. I have authored numerous comprehensive publications that highlight my strong expertise in pharmaceutical science, biotechnology, and molecular medicine. My diverse skills enable me to excel in complex administrative tasks and create innovative research environments in both industry and academia.

- ✍ **Innovative Visionary in Medical Biotechnology:** Pioneering Chief Scientific Officer with a strategic vision for advancing medical biotechnology, combining technical expertise with a forward-thinking approach to drive innovative research initiatives.
- ✍ **Expert in Translational Research:** Seasoned leader skilled in bridging the gap between laboratory discoveries and clinical applications, ensuring seamless translation of groundbreaking scientific findings into tangible, patient-centred solutions.
- ✍ **Strategic Clinical Pharmacologist:** Accomplished in the field of clinical pharmacology, with a proven ability to design and implement rigorous clinical trials, optimize drug development processes, and ensure the efficacy and safety of pharmaceutical interventions.
- ✍ **Multidisciplinary Team Leadership:** Proficient manager of cross-functional teams, adept at fostering collaboration among scientists, researchers, and clinicians, nurturing a culture of creativity and excellence to achieve ambitious scientific goals.
- ✍ **Regulatory Compliance and Quality Assurance:** Expert in navigating complex regulatory landscapes, ensuring compliance with stringent standards and protocols while maintaining the highest level of quality assurance throughout research and development processes.
- ✍ **Results-Driven Scientific Innovation:** Demonstrated track record of transforming scientific concepts into tangible outcomes, delivering pioneering therapies and technologies that significantly impact the healthcare landscape.

SIGNATURE SKILLS

★ Molecular Medicine ★ Medical Biotechnology ★ Clinical Pharmacology ★ Clinical Pharmacokinetics ★ Pharmacogenomics
★ Pharmacogenetics ★ Systems Pharmacology ★ Population PK ★ PK/PD Modelling ★ Simulation / R (Programming Language) ★ BA/BE Studies (Bioavailability/Bioequivalence) ★ Affymetrix/Agilent Mouse & Human Arrays ★ Agilent miRNA array ★ LC-MS/MS analyses
★ Bioinformatics ★ Whole Genome Sequencing (WGS) / miRNA Sequencing ★ Nutraceuticals / Phytopharmaceuticals / Probiotics
★ Formulation of dosage forms/Nano-formulation

PROFESSIONAL NARRATIVE

Chief Scientific Officer (2020 to Present)
Phytoveda/Viridis Biopharma, Mumbai, IN

- ✍ **Guiding High-Caliber Scientific Teams:** Mentor and supervise a dedicated team of PhD-level scientists and junior researchers across diverse therapeutic areas, ensuring a motivated and focused research environment.
- ✍ **Architect of Cutting-Edge Laboratory Facilities:** Plan and oversee the construction and establishment of a state-of-the-art in vitro cell culture and molecular bioscience laboratory, equipped with advanced instrumentation for innovative research.
- ✍ **Innovative Leadership in Nanotechnology:** Direct the establishment of a pioneering nano-formulation laboratory, overseeing the formulation of lipid and polymeric nanoparticles, driving advancements in drug delivery technologies.
- ✍ **Strategic Decision-Making and Project Oversight:** Hold the pivotal responsibility for 'go/no-go' decisions on all existing research projects, ensuring the alignment of research efforts with company objectives and market demands.
- ✍ **Driving Future Research Initiatives:** Initiate and guide new research projects, shaping the future research trajectory of the company with a forward-thinking and innovative approach.
- ✍ **Global Collaboration and Network Building:** Foster international collaborations by liaising with scientists from various countries, evaluating their research contributions, and establishing strategic partnerships to diversify the company's product portfolio.
- ✍ **Promoting Research-Driven Marketing:** Actively promote research activities related to existing products, providing valuable insights that support the marketing division's strategies and enhance product positioning.
- ✍ **International Publication and Research Advocacy:** Publish research findings in esteemed international journals, amplifying the company's research agenda and contributing to the global scientific community.
- ✍ **Inspiring the Next Generation of Scientists:** Cultivating the talents and passion of budding researchers by serving as PhD Advisor and fuelling their drive to revolutionize cancer treatment through innovative molecular therapies.

Senior Consultant (2018 to Present)
Yorker Health, Inc., New York, USA

- ✍ **Revitalized Strategic Planning:** Spearheaded meticulous analysis of disease burden, comorbidities, and polypharmacy, driving enhanced strategic and pharmacoeconomic initiatives within the organization.
- ✍ **Influential Publication Contributions:** Produced detailed scoping reviews, targeted literature reviews, impactful slide decks and posters, as well as international publications for prominent pharmaceutical companies in the United States, augmenting their market research for new product launches through visionary strategies.
- ✍ **Global Talent Development:** Established and nurtured a proficient technical writing team in India for YorkerHealth, fortifying the company's capabilities and ensuring excellence in communication and documentation.
- ✍ **Precision in Troubleshooting:** Played a pivotal role in troubleshooting analytical methods with precision, swiftly resolving discrepancies, and ensuring seamless operations in the organization.
- ✍ **Guiding FDA Compliance:** Leveraged deep expertise to guide an analytical technical team in aligning activities with rigorous FDA regulations, ensuring compliance and smooth navigation through complex regulatory landscapes.
- ✍ **Catalyst for Product Success:** Provided invaluable insights guiding product manufacturing and launch processes, catalyzing efficient and successful product introductions in the US, EU and ROW markets.

Professor of Pharmaceutical Sciences (2018 to 2020)

SVKM Group of Educational Institutions, Mumbai, IN | School of Pharmacy, University of Mumbai and NMIMS University, Mumbai, IN

- ✚ **Elevated Research Impact Through High-Profile Biomedical Publications:** Achieved excellence in crafting comprehensive articles published in renowned biomedical journals
- ✚ **Visionary Clinical Trials and Innovative Contributions to Population Pharmacokinetics Research:** Authored two influential international publications based on pivotal clinical trial data, shedding light on population pharmacokinetics of nutraceuticals from a cohort of 100 human volunteers
- ✚ **Exceptional Student Engagement and Positive Feedback:** Garnered overwhelmingly positive feedback from an outstanding 99.5% of class participants, reflecting exceptional teaching quality and student satisfaction
- ✚ **Pioneering Research in International Forums:** Surpassed expectations by generating 18 international, peer-reviewed journal articles, contributing significantly to the global scientific discourse
- ✚ **Breakthrough Patents:** Meticulously devised and executed the preparation and filing of two patents for groundbreaking nano-bio-formulations aimed at treating aggressive, drug-resistant brain and kidney cancers.

Head / Director / Professor Of Pharmaceutical Sciences (2008 to 2018)

Amrita University – Amrita Institute of Medical Sciences and Research Centre, Kerala, IN

Revolutionizing Clinical Research and Ethical Oversight

- ✚ Directed Pfizer-Amrita Clinical Research Centre. Key Member of Institutional Ethics Committee for Clinical Research.

Architect of Cutting-Edge Research Infrastructure

- ✚ Directed and Administered Amrita School of Pharmacy. Pioneered construction of two state-of-the-art research floors with advanced laboratory facilities

Empowering Future Scholars and Researchers

- ✚ Mentored 45 Master's and 2 Ph.D.-level students. Invested significant time, energy, and resources in fostering their growth.

Navigating Cancer Research and Pharmacogenomics

- ✚ Led cutting-edge cancer research and pre-clinical trials. Conducted groundbreaking pharmacokinetics research and pharmacogenomic microarray studies. Explored cutting-edge systems pharmacology approaches for cancer chemoprevention.

Driving Innovation in MicroRNA Profiling and RNA Interference

- ✚ Served as Principal Investigator in pioneering microRNA microarray profiling of ellagic acid and guggulsterone. Acted as Co-Principal Investigator in multi-dimensional project investigating fusion transcripts in cancer cells, emphasizing RNA interference (RNAi)

Securing Substantial Research Funding

- ✚ Successfully obtained a total of INR 2.0 crores in crucial research funding, fueling impactful initiatives and breakthroughs

ACADEMIC ACHIEVEMENTS

Course Director / Instructor: University of Mumbai (2019 to 2020)

- ✚ **Master of Pharmacy Courses:** Advanced Biopharmaceutics & Pharmacokinetics, Computer-Aided Drug Development, Regulatory Affairs, Drug Delivery Systems, Cellular & Molecular Pharmacology, Laboratory
- ✚ **Bachelor of Pharmacy Courses:** Nutraceuticals & Dietary Supplements, Pharmaceutical Biotechnology, Pharmaceutics, Laboratory

Course Director / Instructor: NMIMS University (2018 to 2019)

- ✚ **Master of Pharmacy Courses:** Advanced Biopharmaceutics & Pharmacokinetics, Drug Regulatory Affairs & Quality Systems, Regulatory Affairs, Pharmaceutics Laboratory

Visiting Professor: NCRD's Sterling Institute of Pharmacy (2018 to 2019)

- ✚ **Bachelor of Pharmacy Courses:** Drug Discovery & Clinical Pharmacy

Course Director / Instructor: Amrita University (2008 to 2018)

- ✚ **PhD, Master of Pharmacy/Biotechnology, Bachelor of Pharmacy/Biotechnology, MTech Nanotechnology/Molecular Medicine Courses:** Advanced Pharmacogenomics, Clinical Pharmacokinetics, Introduction to Pharmacokinetics & Pharmacodynamics, Advanced Discovery Biology, Methods in Transcriptional & Translational Analysis, Advanced Human Biology & Translational Medicine

Course Instructor: Rutgers University – Ernest Mario School of Pharmacy (2002 to 2008)

- ✚ **PharmD Courses:** Biopharmaceutics & Pharmacokinetics, Pharmacy Practice, Drug Delivery, Laboratory

EDUCATION

Doctor of Philosophy in Pharmaceutical Sciences, 2002-2008

- ✚ Rutgers, The State University of New Jersey – Ernest Mario School of Pharmacy, NJ, USA (GPA: 3.906 / 4.0)

Master of Pharmacy in Pharmaceutics | First Class with Distinction, 1998-2001

- ✚ University of Mumbai – K.M. Kundnani College of Pharmacy, Mumbai, IN

Bachelor of Pharmacy | First Class (First Rank in University, 1997)

- ✚ University of Mumbai – Bharati Vidyapeeth's College of Pharmacy, Mumbai, IN

Please refer to the Annexure for other important details

ANNEXURE

MEMBERSHIP/CERTIFICATIONS

- Good Clinical Practice: National Institutes of Health (NIH) NIDA Clinical Trials Network (CTN), Expires: 2026
- Pharmaceutical Modeling & Simulation (PUMAS/Julia): University of Maryland School of Pharmacy, 2020
- Registered Pharmacist: Maharashtra State Pharmacy Council, India

INTERNATIONAL PUBLICATIONS

3500 Citations, h-Index: 24, i10 Index: 38 - Cumulative Impact Factor: 305.22

- Bhaskar A, Zhou Y, **Nair S. Editorial:** Current insights into pharmacogenomics of noncoding RNAs for cancer therapy. **GenoMed Connect** 2025.
- Bhaskar A, Sharma B, Trivedi J, Moorthy M, Dhananya S, Ramaswamy G, Mehta D, **Nair S.** Whole genome circRNA profiling of *Withania somnifera* in SK-N-SH human neuroblastoma cells. **Drug Metabolism and Personalized Therapy** 2025.
- Moitra R, **Nair S.** Current insights into regulation of Alzheimer's disease signal transduction pathways by circular RNAs. **Indian Drugs** 2025.
- Vaidya N, Agarwal R, Kshirsagar P, Ganu G, Nagore D, Mehta A, Vora A, **Nair S.** Safety and tolerability of *Withania somnifera* root extract in humans: a randomized, double-blind, placebo-controlled clinical trial. **Food Science and Nutrition** 2025 (Accepted for publication) (**Impact Factor 3.6**).
- Sharma E, Jadhav N, Ajgaonkar S, Gujrathi G, Sharma B, Moorthy M, Dhananya S, Ramaswamy G, Mehta D, **Nair S.** Whole genome transcriptomic profiling of *Withania somnifera* in SK-N-SH human neuroblastoma cells. **Frontiers in Molecular Neuroscience** 2025 Jun 25:18:1512727 (**Impact Factor 3.5**).
- Sharma E, Mehta D, Sahare S, Ajgaonkar S, Saha P, Bhaskar A, Trivedi J, Dhananya S, Moorthy M, Ramaswamy G, **Nair S.** RNA sequencing of the lncRNA regulome modulated by *Withania somnifera* in human neuroblastoma SK-N-SH cells. **Molecular Biology Reports** 2025 (**Impact Factor 2.6**).
- Vivek P, **Nair S.** Current insights into regulation of diabetic foot ulcer by circular RNAs. **Indian Drugs** 2025.
- Vaidya N, Agarwal R, Dipankar DG, Patkar H, Ganu G, Nagore D, Godse C, Mehta A, Mehta D, **Nair S.** Efficacy and safety of *Boswellia serrata* and *Apium graveolens* L. extract against knee osteoarthritis and cartilage degeneration: A randomized, double-blind, multicenter, placebo-controlled clinical trial. **Pharmaceutical Research** (2025) 42:249-269 (**Impact Factor 3.5**).
- Sharma E, Ganu G, Mehta D, **Nair S.** An open-label, single dose, safety and pharmacokinetic study of *Withania somnifera* root extract in healthy volunteers. **Drug Metabolism and Personalised Therapy** (2025) 40(1):23-34.
- Thakkar N, Gajera G, Mehta D, **Nair S,** Kothari V. *Withania somnifera* root extract confers beneficial effects on health and lifespan of the model worm *Caenorhabditis elegans*. **Drug Target Insights** (2025) 19(1): 18-30.
- Panda S, Subudhi E, Routray SP, **Nair S.** Systems pharmacology of phytochemical anacardic acid in the chemoprevention of hepatocellular carcinoma. **Drug Metabolism and Personalised Therapy** (2025) 40(2):107-120.
- Muhammad Puhari SS, Mehta D, Bhaskar A, Basudkar V, Saha P, Ajgaonkar S, Trivedi J, Dhananya S, Moorthy M, Ramaswamy G, Zhou Y, **Nair S.** Regulation of small noncoding microRNAome by *Withania somnifera* in human neuroblastoma SK-N-SH cells. **Molecular Genetics and Genomics** 2025 Manuscript under review (**Impact Factor 2.2**).
- Saha P, Maniar D, Mehta D, **Nair S.** Current insights into transcriptional role(s) for Ashwagandha (*Withania somnifera*) in inflammation and aging. **Frontiers in Nutrition** (2024) Vol. 11 (**Impact Factor 6.59**).
- Papachristos A, Cusato J, **Nair S,** Maggo S, Suppiah V. **Editorial:** Utilization of pharmacogenetics in clinical practice. **Frontiers in Genetics** (2024) Aug 20:15:1470698 (**Impact Factor 4.1**).
- Gandhi M, Sharma B, **Nair S,** Vaidya ADB. Current insights into CAR T-cell-based therapies for myelodysplastic syndrome. **Pharmaceutical Research** (2024) 41(9): 1757-1773 (**Impact Factor 3.5**).
- Wangikar P, Chaudhari P, Sharma E, Godse C, Vora A, **Nair S.** Acute and sub-chronic oral GLP toxicity of *Withania somnifera* root extract in Sprague Dawley rats. **Drug Metabolism and Personalized Therapy** (2024) 39:145-158.
- Basudkar V, Gujrati G, Maniar D, Mehta D, **Nair S.** Emerging vistas for Ashwagandha (*Withania somnifera*) in inflammaging. **Pharmaceuticals** 2024; 17(5):597 (**Impact Factor 4.3**).
- Trivedi J, Desai A, Saha P, Ajgaonkar A, Nabar S, Momin M, Muzumdar I, **Nair S.** Current insights into signature microRNA networks and signal transduction in osteosarcoma. **Current Pharmacology Reports** (2024) 10:159-206.
- Johnson TS, **Nair S,** de Souza A, Hingorani L. Dalbergia sissoo Roxb. Ex-DC. – A monograph. **Pharmacognosy Reviews** (2024) 18(36): 137-150 597 (**Impact Factor 1.3**).
- Sharma E, Ajgaonkar S, Panda S, Mehta D, **Nair S.** New vistas for Ashwagandha (*Withania somnifera*) in signal transduction of inflammation and aging. Manuscript communicated. 2025.
- Jadhav N, Panda S, Saha P, Mehta D, **Nair S.** A randomized, double-blind, placebo-controlled trial of Ashwagandha (*Withania somnifera*) in healthy aging: effects on modulation of key serum protein biomarkers. Manuscript in preparation.
- Basudkar V, Ajgaonkar S, Mehta D, **Nair S.** Current clinical insights into circRNAs and signal transduction in diabetic nephropathy. **Diabetic Nephropathy** 2023. <https://doi.org/10.1515/dine-2023-0007>
- Saha P, Basudkar V, Mehta T, Maniar D, **Nair S.** Emerging roles for vitamin K2-7 in cellular energy pathways. **The Indian Practitioner** 2023; 76(8): 23-28.
- Pimple P, Sawant A, **Nair S,** Sawarkar S. Current insights into targeting strategies for diseases of the posterior eye segment. **Critical Reviews in Therapeutic Drug Carrier Systems** 2023 (**Impact Factor 4.889**).
- Gada Y, Pandey A, Jadhav N, Ajgaonkar S, Mehta D, **Nair S.** New vistas in microRNA regulatory interactome in neuropathic pain. **Frontiers in Pharmacology** 2022; 12: 778014 (**Impact Factor 5.810**).
- Gandhi M, Bakhai V, Trivedi J, Mishra A, De Andres F, LLerena A, Sharma R, **Nair S.** Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction. **Translational Oncology** 2022; 25: 101532 (**Impact Factor 4.803**).
- Pandey A, Ajgaonkar S, Jadhav N, Saha P, Gurav P, Mehta D, **Nair S.** New vistas in noncoding RNA regulatory interactome in the pathogenesis of diabetes. **Pharmaceuticals** 2022; 15(10):1269 (**Impact Factor 5.215**).
- Jadhav N, Pandey A, Ajgaonkar S, Gada Y, Saha P, Gurav P, Basudkar V, Jadhav S, Mehta D, **Nair S.** Emerging roles for vitamin K2-7 as a health-beneficial nutraceutical: Challenges and opportunities. **Frontiers in Pharmacology** 2022; 13:896920 (**Impact Factor 5.810**).
- Vaidya R, Godse C, Jadhav S, Saha P, Ajgaonkar S, Pandey A, Gurav P, Jadhav N, Mehta D, **Nair S.** Current insights into the health-beneficial effects of vitamin K2-7 in neuropathic pain. **Biomedical Journal of Scientific & Technical Research** 2022; 42(3): 33679-33687 (**Impact Factor 1.095**).
- Krishnan K, **Nair S,** Mehta D. Bacillus endospore probiotics are a promising intervention for mitigation of metabolic endotoxemia. Book chapter in Probiotics, Prebiotics, Synbiotics and Postbiotics. 2022; (**Springer Nature, Singapore**).

- Jain R, Sodvadiya M, Mahadik A, Bakhai V, Vasistha A, Gadekar E, Vora A, Kong Ah-Ng Tony, Llerena A, Sanghavi RK, **Nair S**. Clinical trials of broccoli in combination with moringa or pomegranate in Indian population. Manuscript in preparation.
- Vasistha A, Bakhai V, Mahadik A, Sodvadiya M, Jain R, Gadekar E, Vora A, Kong Ah-Ng Tony, Llerena A, Sanghavi RK, **Nair S**. Clinical trials of green tea in combination with moringa, pomegranate or soyabean in Indian population. Manuscript in preparation.
- Mishra A, Gurav P, De Andres F, Peñas-Lledó EM, Llerena A, **Nair S**. Current insights into interethnic variability and noncoding RNA in population pharmacogenetics of depression. Manuscript communicated.
- Trivedi J, Nabar S, Jadhav R, Khambete M, **Nair S**. Emerging roles for noncoding RNA in the systems pharmacology of neuropathic pain. Manuscript in preparation.
- Muzumdar I, **Nair S**. Emerging roles for TREM-2 signaling in inflammation and carcinogenesis. Manuscript in preparation.
- Nirale P, Prabhakar B, **Nair S**. Current insights into early translational research for arbovirus disease theranostics. Manuscript in preparation.
- Shah D, Gandhi M, Kumar A, Cruz-Martins N, Sharma R, **Nair S**. Current insights into epigenetics, noncoding RNA interactome and pharmacokinetics of dietary polyphenols in cancer chemoprevention. **Critical Reviews in Food Science and Nutrition** 2021; 1-37 (**Impact Factor 11.176**).
- Mali A, Sawant A, Mahadik A, **Nair S**. Immunotherapy for autoimmune diseases. Book chapter in Immunotherapy: A novel facet of modern therapeutics. 2021; 63-115; Online ISBN 978-981-15-9038-2 (**Springer, Singapore**).
- Date V, **Nair S**. Emerging vistas in CAR T-cell therapy: Challenges and Opportunities in Solid Tumors. **Expert Opinion on Biological Therapy** 2020; 1-16 (In press). doi: 10.1080/14712598.2020.1819978 (**Impact Factor 3.974**).
- Gandhi M, **Nair S**. New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction. **Life Sciences** 2020; 257:118-123 (**Impact Factor 3.647**).
- Penas-Lledo E, Teran E, Sosa-Macias M, Galaviz-Hernandez C, Gil J, **Nair S**, et al. Challenges and opportunities for clinical pharmacogenetic research studies in resource-limited settings: Conclusions from the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting. **Clinical Therapeutics** 2020; 42(8): 1595-1610 (**Impact Factor 3.119**).
- Vasistha A, Kothari R, Mishra A, De Andres F, Llerena A, **Nair S**. Current insights into interethnic variability in testicular carcinogenesis: Population pharmacogenetics, clinical trials, chemotherapy-induced toxicities,, and molecular signal transduction. **Current Topics in Medicinal Chemistry** 2020; 20(20): 1824-1838 (**Impact Factor 3.402**).
- Gulati I, Patel H, Prabhakar B, **Nair S**. Current translational insights into MGMT methylation regulating temozolomide sensitivity and resistance in glioblastoma multiforme. **Current Pharmacogenomics and Personalized Medicine**. Bentham. 2020; 17:1-18.
- Sodvadiya M, Patel H, Mishra A, **Nair S**. Emerging insights into anticancer chemo-preventive activities of nutraceutical Moringa oleifera: molecular mechanisms, signal transduction and in vivo efficacy. **Current Pharmacology Reports**. Springer Switzerland. 2020; 6(2): 1-16.
- Jain R and **Nair S**. Sandalwood oil for the chemoprevention of skin cancer: Mechanistic insights, anti-inflammatory and in vivo anticancer potential. **Current Pharmacology Reports**. Springer Switzerland. 2019; 5(5): 345-358.
- Mishra A, Kataria I, **Nair S**. Pharmacokinetics and systems pharmacology of anti-CD47 macrophage immune checkpoint inhibitor Hu5F9-G4. **Current Pharmacogenomics and Personalized Medicine**. Bentham. 2019; 17(1): 14-24.
- Nair S** and Llerena A. Editorial: New vistas in personalized medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics. **Drug Metabolism and Personalized Therapy** 2018; 33(2): 61-64.
- Nair S** and Kong AN. Emerging roles for clinical pharmacometrics in cancer precision medicine. **Current Pharmacology Reports** 2018; 3(3):1-8.
- Nair S**, Iyer A, Vijay V, Bandlamudi S and Llerena A. Pharmacokinetics and systems pharmacology of monoclonal antibody olaratumab for inoperable soft tissue sarcoma. **Advances in Modern Oncology Research** 2017; 3(3): 1-12.
- Nair S**. Pharmacometrics and systems pharmacology of immune checkpoint inhibitor nivolumab in cancer translational medicine. **Advances in Modern Oncology Research** 2016; 2(1):18-31 (Article was Second amongst Top Ten Most Accessed articles of 2015/2016 for this journal).
- Nair S** and Kong AN. Pharmacometrics of nutraceutical sulforaphane and its implications in prostate cancer prevention. **Journal of Chinese Pharmaceutical Sciences** 2016; 25(1):12-22.
- Nair S**. Current insights into the molecular systems pharmacology of lncRNA-miRNA interactions and implications in cancer translational medicine. **AIMS Molecular Science** 2016; 3(2):104-124.
- Fuentes F, Gomez Y, Paredes-Gonzalez X, Barve A, **Nair S**, Yu S, Saw CLL, Kong AN. Nrf2-mediated antioxidant and detoxifying enzyme induction by a combination of curcumin and sulforaphane. **Journal of Chinese Pharmaceutical Sciences** 2016; 25(8):559-569.
- Nair S**, Liew C, Khor TO, Cai L, Kong AN. Elucidation of regulatory interaction networks underlying human prostate adenocarcinoma. **Journal of Chinese Pharmaceutical Sciences** 2015; 24(1): 12-27.
- Nair S** and Kong AN. Architecture of miRNA regulatory networks in cancer chemoprevention. **Current Pharmacology Reports** 2015; 1:89-101.
- Nair S**, Liew C, Khor TO, Cai L, Kong AN. Differential signaling regulatory networks governing hormone-refractory prostate cancers. **Journal of Chinese Pharmaceutical Sciences** 2014; 23(8):507-510.
- Neelakandan K, Babu P, **Nair S**. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. **Current Cancer Drug Targets** 2012; 12(6):716-40 (**Impact Factor 4.771**).
- Babu P, Neelakandan K, Menon KN, Ganesan TS, **Nair S**. Pharmacogenomics of natural dietary phenolic antioxidant ellagic acid in HepG2 and PLC/PRF/5 human hepatocellular carcinoma cells. **Journal of Cancer Research and Therapeutics** 2012; Abstract P27; 8(1):S36a (**Impact Factor 1.326**).
- Neelakandan K, Babu P, Menon KN, Ganesan TS, **Nair S**. Global gene expression profiling of anti-cancer chemopreventive effects of dietary phytochemical guggulsterone in human hepatocellular carcinoma. **Journal of Cancer Research and Therapeutics** 2012; Abstract P26; 8(1):S36b (**Impact Factor 1.326**).
- Nair S**, Barve A, Khor TO, Shen GX, Lin W, Chan JY, Cai L, Kong AN. Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. **Acta Pharmacologica Sinica** 2010; 31(9):1223-1240 (**Impact Factor 5.064**).
- Barve A, Khor TO, **Nair S**, Reuhl K, Suh N, Reddy B, Newmark H, Kong AN. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. **International Journal of Cancer** 2009; 124(7): 1693-9 (**Impact Factor 6.513**).
- Prawan A, Khor TO, **Nair S**, Gopalakrishnan A, Kong AN. Pharmacogenomic profile of Tocotrienol/Tocopherol complex in the small intestine of Nrf2 knockout and C57BL/6J mice. **Proceedings of the 14th Biennial Meeting of the Society for Free Radical Research International** 2008 at Beijing, China. Publication date: 18-10-2008.
- Nair S**, Doh ST, Chan JY, Kong AN, Cai L. Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. **British Journal of Cancer** 2008; 99(12):2070-82 (**Impact Factor 6.210**).
- Barve A, Khor TO, **Nair S**, Kong AN. Pharmacogenomic profile of Novasoy®-soy isoflavone concentrate in the prostate of Nrf2 deficient and wild type mice. **Journal of Pharmaceutical Sciences** 2008; 97(10):4528-45 (**Impact Factor 3.300**).
- Shen G, Khor TO, Hu R, Yu S, **Nair S**, Ho CT, Reddy BS, Huang MT, Newmark HL, Kong AN. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. **Cancer Research** 2007; 67(20):9937-44 (**Impact Factor 9.727**).
- Nair S**, Hebbar V, Shen G, Gopalakrishnan A, Khor TO, Yu S, Xu C, Kong AN. Synergistic Effects of a Combination of Dietary Factors Sulforaphane and (-) Epigallocatechin-3-gallate in HT-29 AP-1 Human Colon Carcinoma Cells. **Pharmaceutical Research** 2008; 25(2):387-99 (**Impact Factor 4.456**).
- Prawan A, Keum YS, Khor TO, Yu S, **Nair S**, Li W, Hu L, Kong AN. Structural influence of isothiocyanates on the antioxidant response element (ARE)-mediated heme oxygenase-1 (HO-1) expression. **Pharmaceutical Research** 2008; 25(4):836-44 (**Impact Factor 4.456**).

- ✉ **Nair S**, Li W, Kong AN. Natural dietary anti-cancer chemopreventive compounds: Redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells. **Acta Pharmacologica Sinica** 2007; 28(4):459-72. Figure from this article was featured on the Journal Cover Page; Article was top download for 2007 in this journal (**Impact Factor 5.064**).
- ✉ Prawan A, Keum YS, Khor TO, Yu S, **Nair S**, Kong AN. Structure-activity relationship in the induction of heme oxygenase-1 by isothiocyanates in HepG2 cells. **Cancer Research** 2007; Abstract 3343; 67(9 Supplement):3343 (**Impact Factor 9.727**).
- ✉ **Nair S**, Xu C, Shen G, Hebbar V, Gopalakrishnan A, Hu R, Jain MR, Liew C, Chan JY, Kong A.-N. T. Toxicogenomics of endoplasmic reticulum stress inducer tunicamycin in the small intestine and liver of Nrf2 knockout and C57BL/6J Mice. **Toxicology Letters** 2007; 168(1):21-39 (**Impact Factor 3.858**).
- ✉ Hu R, Shen G, Yerramilli UR, Lin W, Xu C, **Nair S**, Kong AN. In vivo pharmacokinetics, activation of MAPK signaling and induction of phase II/III drug metabolizing enzymes/transporters by cancer chemopreventive compound BHA in the mice. **Archives of Pharmacol Research** 2006; 29(10):911-20 (**Impact Factor 2.934**).
- ✉ **Nair S**, Xu C, Shen G, Hebbar V, Gopalakrishnan A, Hu R, Jain MR, Lin W, Keum YS, Liew C, Chan JY, Kong AN. Pharmacogenomics of phenolic antioxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57BL/6J Mice. **Pharmaceutical Research** 2006; 23(11):2621-37 (**Impact Factor 4.456**).
- ✉ Gopalakrishnan A, Xu C, **Nair S**, Chen C, Hebbar V, Kong AN. Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. **Archives of Pharmacol Research** 2006; 29(8):633-44 (**Impact Factor 2.934**).
- ✉ Khor TO, Hu R, Shen G, Jeong WS, Hebbar V, Chen C, **Nair S**, Reddy B, Chada K, Kong AN. Pharmacogenomics of cancer chemopreventive isothiocyanate compound sulforaphane in the intestinal polyps of ApcMin/+ mice. **Biopharmaceutics and Drug Disposition** 2006; 27(9):407-20 (**Impact Factor 1.710**).
- ✉ Shen G, Xu C, Hu R, Jain MR, Gopalakrishnan A, **Nair S**, Huang MT, Chan JY, Kong AN. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. **Molecular Cancer Therapeutics** 2006; 5(1):39-51 (**Impact Factor 5.615**).
- ✉ Xu C, Shen G, Yuan X, Kim JH, Gopalakrishnan A, Keum YS, **Nair S**, Kong AN. ERK and JNK signaling pathways are involved in the regulation of activator protein-1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. **Carcinogenesis** 2006; 27 (3): 437-45 (**Impact Factor 5.402**).
- ✉ Shen G, Xu C, Hu R, Jain MR, **Nair S**, Lin W, Yang CS, Chan JY, Kong AN. Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. **Pharmaceutical Research** 2005; 22(11):1805-20 (**Impact Factor 4.456**).
- ✉ Chen C, Pung D, Leong V, Hebbar V, Shen G, **Nair S**, Li W, Kong AN. Induction of detoxifying enzymes by garlic organosulfur compounds through transcription factor Nrf2: effect of chemical structure and stress signals. **Free Radical Biology and Medicine** 2004; 37(10):1578-90 (**Impact Factor 6.170**).
- ✉ **Nair S**, Hebbar V, Shen G, Keum YS, Kong AN. Differential effects of a combination of sulforaphane and epigallocatechin-3-gallate in HT-29 AP-1 and PC-3 AP-1 stable cell lines. **Cancer Research** 2005; Abstract 6087; 65(9 Supplement):1431-1432 (**Impact Factor 9.727**).
- ✉ Shen G, Hebbar V, **Nair S**, Xu C, Li W, Lin W, Keum YS, Han J, Gallo MA, Kong AN. Regulation of Nrf2 transactivation domain activity. The differential effects of mitogen-activated protein kinase cascades and synergistic stimulatory effect of Raf and CREB-binding protein. **Journal of Biological Chemistry** 2004; 279(22):23052-60 (**Impact Factor 5.328**).
- ✉ Kim BR, Hu R, Keum YS, Hebbar V, Shen G, **Nair S**, Kong AN. Effects of glutathione on antioxidant response element-mediated gene expression and apoptosis elicited by sulforaphane. **Cancer Research** 2003; 63(21):7520-5 (**Impact Factor 9.727**).

CONFERENCE TALKS

Education, Values, and Attitudes and Relevance of Cultural context for Clinical Research: Views from India

- ✉ CIOMS-RIBEF Symposium on Ethnicity, Sociocultural Context, and Education for Health Research, Spain (2019)

Cancer Pharmacogenomics and Clinical Research

- ✉ Consortium for Clinical Pharmacology for Cancer Research, Mumbai, India (2019)

Clinical Trials on Nutraceuticals in Indian Population

- ✉ Rutgers, The State University of New Jersey, USA (2016)

Pharmacometrics and Systems Pharmacology of Immune Checkpoint Inhibitor Nivolumab

- ✉ Society for the Study of Xenobiotics, Bengaluru, India (2016)

Pharmacometrics in the Translational Pharmacology Paradigm

- ✉ Omics Conferences, Brisbane, Australia (2015)

Development of an Indian Pharmacogenomics Network

- ✉ European Society of Pharmacogenomics and Personalized Therapy, Budapest, Hungary (2015)

Acceleration of Cancer Biomarker Discovery by RNA Network Landscapes

- ✉ World Gene Conference, Haikou, China (2014)

Regulatory Architecture of RNA Networks in the Cancer Drug Discovery Pipeline

- ✉ Molecular Medicine Congress, Haikou, China (2014)

EDITORIAL AFFILIATIONS

- ✉ Co-Editor in Chief, Current Pharmacogenomics & Personalized Medicine, Bentham, UAE (2018-Present)
- ✉ Associate Editor, Frontiers in Pharmacology, Frontiers, Switzerland (2022-Present)
- ✉ Associate Editor, Frontiers in Genetics, Frontiers, Switzerland (2022-Present)
- ✉ Associate Editor, Drug Metabolism & Personalized Therapy, Walter De Gruyter, Germany (2015-Present)
- ✉ Regional Editor (Asia), GenoMed Connect, Scifinity Publishing, UAE (2024-Present)
- ✉ Section Editor, Genomics and Genetics, Current Pharmacology Reports, Springer, USA (2015-Present)
- ✉ Editorial Board, Advances in Modern Oncology Research, Bilingual, Singapore (2015-2023)
- ✉ Editorial Board, Oncology Research, Academic Publishing Pte. Ltd., Singapore (2023-Present)

AWARDS WON

- ✉ Contribution: Asia representative for World Health Organization (WHO) CIOMS-RIBEF guidelines on clinical pharmacogenetics research in resource-limited settings (2020)
- ✉ Invitation: Research Progress Reviewer for National Research Foundation (NRF), South Africa (2020, 2023)

- ✍ Certification: Pharmaceutical Modeling and Simulation - (PUMAS/Julia programming by University of Maryland, Baltimore, USA) (2020)
- ✍ Certification: Practical Introduction to the Command Line – Coursera (2020)
- ✍ Certification: Genomic Data Science with Galaxy – Coursera (2020)
- ✍ Certification: U.S. National Institutes of Health (NIH) NIDA - Clinical Trials Network (2019)
- ✍ Invitation: Ph.D. Examiner in Pharmacology – Amrita School of Medicine, Amrita University (2019)
- ✍ Invitation: Ph.D. Examiner in Pharmaceutical Biotechnology – Bharati Vidyapeeth University (2019)
- ✍ Invitation: Ph.D. Examiner in Pharmaceutical Sciences – JSS University (2018)
- ✍ Top 1% of Peer Reviewers in Biomedical Sciences – Publons (2017 & 2018)
- ✍ Researcher in Spotlight: Advances in Modern Oncology Research (2017)
- ✍ Outstanding Reviewer – Pharmaceutical Research (2010 & 2011)
- ✍ Publons/Web of Science Profile – Over 400 verified peer reviews and 100 verified editor records <https://publons.com/researcher/468891/dr-sujit-nair/>

PROFESSIONAL ASSOCIATIONS

- ✍ Member, International Expert Panel, National Medical Research Council (NMRC) and A*STaR, Ministry of Health, Government of Singapore (2014 to 2020)
- ✍ Ad hoc Reviewer, NMRC and A*STaR (2022; 2023)
- ✍ Member, Consortium for Clinical Pharmacology for Cancer Research (2019-Present)
- ✍ Member, International Society for Xenobiotics, ISSX (2017)
- ✍ Member, European Society for Pharmacogenomics and Personalized Therapy, ESPT (2015-Present)

PATENTS

- ✍ Synergistic efficacy of Geraniin and Corilagin against Liver Diseases
- ✍ Novel Nanobio-formulation of Temozolomide Plus MGMT DNA Repair Inhibitor for Drug-Resistant Glioblastoma or Brain Cancer.
- ✍ Novel Nanobio-formulation of Pazopanib Plus MEK/ERK MAPK Inhibitor for Drug-Resistant Renal Cell Carcinoma or Kidney Cancer.
- ✍ Novel Nanobio-formulation of MEK/ERK MAPK Inhibitor and Approved Drug for Retinoblastoma.